biostudies-literatureScott WCNCATS NIH HHSNIA NIH HHSNIAID NIH HHSNational Institutes of Health1318-1328.e5https://www.ebi.ac.uk/biostudies/studies/S-EPMC8035132biostudies-literatureUnknown147(4)<h4>Background</h4>Aspirin-exacerbated respiratory disease (AERD) is a mechanistically distinct subtype of chronic rhinosinusitis with nasal polyps (CRSwNP). Although frequently associated with type 2 inflammation, literature characterizing the milieu of inflammatory cytokines and lipid mediators in AERD has been conflicting.<h4>Objective</h4>We sought to identify differences in the upper airway inflammatory signature between CRSwNP and AERD and determine whether endotypic subtypes of AERD may exist.<h4>Methods</h4>Levels of 7 cytokines representative of type 1, type 2, and type 3 inflammation, and 21 lipid mediators were measured in nasal mucus from 109 patients with CRSwNP, 30 patients with AERD, and 64 non-CRS controls. Differences in inflammatory mediators were identified between groupThe Journal of allergy and clinical immunologyInflammatory heterogeneity in aspirin-exacerbated respiratory disease.PMC8035132R01 AG065550K23 AI118804R21 AI142321UL1 TR000445Scott WCChowdhury NIChandra RKCahill KNDennis SSnyder JTurner JHLi PSheng QHuang LCBauer AMMilne GLfalseInflammatory heterogeneity in aspirin-exacerbated respiratory disease.<h4>Background</h4>Aspirin-exacerbated respiratory disease (AERD) is a mechanistically distinct subtype of chronic rhinosinusitis with nasal polyps (CRSwNP). Although frequently associated with type 2 inflammation, literature characterizing the milieu of inflammatory cytokines and lipid mediators in AERD has been conflicting.<h4>Objective</h4>We sought to identify differences in the upper airway inflammatory signature between CRSwNP and AERD and determine whether endotypic subtypes of AERD may exist.<h4>Methods</h4>Levels of 7 cytokines representative of type 1, type 2, and type 3 inflammation, and 21 lipid mediators were measured in nasal mucus from 109 patients with CRSwNP, 30 patients with AERD, and 64 non-CRS controls. Differences in inflammatory mediators were identified between group2021-01-01T00:00:00Z2021 Apr2025-04-29T11:31:21.645Z2025-04-06T19:54:18.593ZS-EPMC80351323318972910.1016/j.jaci.2020.11.001